Po‐Shen Ko

418 total citations
37 papers, 260 citations indexed

About

Po‐Shen Ko is a scholar working on Hematology, Oncology and Pathology and Forensic Medicine. According to data from OpenAlex, Po‐Shen Ko has authored 37 papers receiving a total of 260 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Hematology, 12 papers in Oncology and 11 papers in Pathology and Forensic Medicine. Recurrent topics in Po‐Shen Ko's work include Lymphoma Diagnosis and Treatment (10 papers), Multiple Myeloma Research and Treatments (7 papers) and Hematopoietic Stem Cell Transplantation (7 papers). Po‐Shen Ko is often cited by papers focused on Lymphoma Diagnosis and Treatment (10 papers), Multiple Myeloma Research and Treatments (7 papers) and Hematopoietic Stem Cell Transplantation (7 papers). Po‐Shen Ko collaborates with scholars based in Taiwan, United States and South Korea. Po‐Shen Ko's co-authors include Liu H, Chia‐Jen Liu, Hao‐Yuan Wang, Liang-Tsai Hsiao, Jyh-Pyng Gau, Tzeon-Jye Chiou, Yao‐Chung Liu, Sheng‐Hsuan Chien, Jyh‐Pyng Gau and Chun‐Yu Liu and has published in prestigious journals such as Blood, PLoS ONE and Scientific Reports.

In The Last Decade

Po‐Shen Ko

34 papers receiving 257 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Po‐Shen Ko Taiwan 10 87 80 73 55 49 37 260
Juan José Rodríguez‐Sevilla Spain 10 62 0.7× 51 0.6× 40 0.5× 21 0.4× 29 0.6× 34 211
Atsuko Mugitani Japan 8 94 1.1× 78 1.0× 54 0.7× 27 0.5× 17 0.3× 28 219
Luis Aversa Argentina 10 126 1.4× 73 0.9× 71 1.0× 40 0.7× 25 0.5× 19 336
Chiara Frairia Italy 10 147 1.7× 100 1.3× 59 0.8× 37 0.7× 22 0.4× 24 296
Colin Phipps Diong Singapore 6 46 0.5× 94 1.2× 50 0.7× 36 0.7× 31 0.6× 23 278
Dawn Sheppard Canada 8 124 1.4× 54 0.7× 37 0.5× 34 0.6× 87 1.8× 17 284
Masanobu Morioka Japan 11 129 1.5× 73 0.9× 53 0.7× 25 0.5× 11 0.2× 64 329
Ambra Paolini Italy 9 77 0.9× 35 0.4× 23 0.3× 23 0.4× 23 0.5× 16 199
Lara Malerba Italy 11 131 1.5× 151 1.9× 84 1.2× 17 0.3× 38 0.8× 18 261
Shin Young Hyun South Korea 10 125 1.4× 86 1.1× 44 0.6× 71 1.3× 11 0.2× 29 269

Countries citing papers authored by Po‐Shen Ko

Since Specialization
Citations

This map shows the geographic impact of Po‐Shen Ko's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Po‐Shen Ko with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Po‐Shen Ko more than expected).

Fields of papers citing papers by Po‐Shen Ko

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Po‐Shen Ko. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Po‐Shen Ko. The network helps show where Po‐Shen Ko may publish in the future.

Co-authorship network of co-authors of Po‐Shen Ko

This figure shows the co-authorship network connecting the top 25 collaborators of Po‐Shen Ko. A scholar is included among the top collaborators of Po‐Shen Ko based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Po‐Shen Ko. Po‐Shen Ko is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Gurion, Ronit, Catherine Thiéblemont, Won Seog Kim, et al.. (2024). Fixed-Duration Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results from Arm 1 of the Epcore NHL-5 Trial. Blood. 144(Supplement 1). 3110–3110. 7 indexed citations
2.
Chang, Kao-Jung, Chun Ma, Yanwen Liang, et al.. (2024). N6-methyladenosine and its epitranscriptomic effects on hematopoietic stem cell regulation and leukemogenesis. Molecular Medicine. 30(1). 196–196. 2 indexed citations
3.
4.
Liu, Chun‐Yu, Chiu‐Mei Yeh, Liang‐Tsai Hsiao, et al.. (2024). Risk factors of early disease progression and decreased survival for multiple myeloma patients after upfront autologous stem cell transplantation. Annals of Hematology. 103(8). 2893–2904. 2 indexed citations
5.
Yang, Ching‐Fen, Liang‐Tsai Hsiao, Po‐Shen Ko, et al.. (2023). Long‐term outcomes of frontline intensification in primary CNS lymphoma: A real‐world single‐center experience. Cancer Medicine. 12(7). 8089–8101. 3 indexed citations
6.
Wang, Hao‐Yuan, Ching‐Fen Yang, Yao‐Chung Liu, et al.. (2023). Surface TREM2 on circulating M-MDSCs as a novel prognostic factor for adults with treatment-naïve diffuse large B-cell lymphoma. Experimental Hematology and Oncology. 12(1). 35–35. 9 indexed citations
7.
Yeh, Chiu‐Mei, Yao‐Chung Liu, Hao‐Yuan Wang, et al.. (2022). Herpes zoster prophylaxis: Essential for treating newly diagnosed multiple myeloma patients. Cancer Medicine. 12(3). 3013–3026. 1 indexed citations
8.
Liu, Chun‐Yu, Chiu‐Mei Yeh, Liang‐Tsai Hsiao, et al.. (2022). Risk Factors and Outcomes of Stem Cell Mobilization Failure in Multiple Myeloma Patients. Transfusion Medicine and Hemotherapy. 50(1). 39–50. 4 indexed citations
9.
Yeh, Chiu‐Mei, Ching‐Fen Yang, Yao‐Chung Liu, et al.. (2022). Prognostic factors in patients with bone marrow hemophagocytosis and its association with hematologic malignancies. Hematological Oncology. 41(1). 167–177. 2 indexed citations
10.
Suzuki, Kenshi, Chang‐Ki Min, Kihyun Kım, et al.. (2021). Carfilzomib, dexamethasone, and daratumumab in Asian patients with relapsed or refractory multiple myeloma: post hoc subgroup analysis of the phase 3 CANDOR trial. International Journal of Hematology. 114(6). 653–663. 4 indexed citations
11.
12.
Ko, Po‐Shen, et al.. (2020). Difference in thrombotic microangiopathy between concurrently and previously diagnosed systemic lupus erythematosus. Journal of the Chinese Medical Association. 83(8). 743–750. 4 indexed citations
13.
Chien, Sheng‐Hsuan, Po‐Ming Chen, Po‐Shen Ko, et al.. (2020). The landscape of BCR‐ABL mutations in patients with Philadelphia chromosome‐positive leukaemias in the era of second‐generation tyrosine kinase inhibitors. Hematological Oncology. 38(3). 390–398. 3 indexed citations
14.
Ko, Po‐Shen, Hao‐Yuan Wang, Chia‐Jen Liu, et al.. (2019). Risk factors and clinical features for post-transplant thoracic air-leak syndrome in adult patients receiving allogeneic haematopoietic stem cell transplantation. Scientific Reports. 9(1). 11795–11795. 8 indexed citations
15.
Yang, Huai‐Che, Li-Yu Fay, Chiu-Mei Yeh, et al.. (2019). Risk Prediction for Early Mortality in Patients with Newly Diagnosed Primary CNS Lymphoma. Journal of Cancer. 10(17). 3958–3966. 8 indexed citations
16.
Wu, Chi-Jung, Po‐Shen Ko, Sheng‐Hsuan Chien, et al.. (2018). Mycobacterial infections in adult recipients of allogeneic hematopoietic stem cell transplantation: A cohort study in a high endemic area. Journal of Microbiology Immunology and Infection. 53(2). 274–282. 16 indexed citations
17.
Liu, Yao‐Chung, Po‐Shen Ko, Hao‐Yuan Wang, et al.. (2017). Cerebrovascular Disease after Allogeneic Hematopoietic Stem Cell Transplantation: Incidence, Manifestations, Risk and Clinical Outcome. Blood. 130. 4527–4527. 1 indexed citations
18.
Ko, Po‐Shen, Hao‐Yuan Wang, Chia‐Jen Liu, et al.. (2017). Clinical-associated characteristics and microbiological features of bloodstream nontyphoidal salmonella infection in adult patients receiving allogeneic hematopoietic stem cell transplantation. Annals of Hematology. 96(9). 1533–1540. 2 indexed citations
19.
20.
Ko, Po‐Shen, et al.. (2013). Acute leukemic appendicitis. International Journal of Hematology. 97(2). 161–162.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Juan José Rodríguez‐Sevilla Breakdown of academic impact, for papers by Atsuko Mugitani Breakdown of academic impact, for papers by Luis Aversa Breakdown of academic impact, for papers by Chiara Frairia Breakdown of academic impact, for papers by Colin Phipps Diong Breakdown of academic impact, for papers by Dawn Sheppard Breakdown of academic impact, for papers by Masanobu Morioka Breakdown of academic impact, for papers by Ambra Paolini Breakdown of academic impact, for papers by Lara Malerba Breakdown of academic impact, for papers by Shin Young Hyun
Rankless by CCL
2026